Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock by unknown
Cazalis et al. Critical Care 2013, 17:R287
http://ccforum.com/content/17/6/R287RESEARCH Open AccessDecreased HLA-DR antigen-associated invariant
chain (CD74) mRNA expression predicts mortality
after septic shock
Marie-Angélique Cazalis1, Arnaud Friggeri1,2, Laura Cavé1, Julie Demaret3, Véronique Barbalat1, Elisabeth Cerrato1,
Alain Lepape1,2, Alexandre Pachot1, Guillaume Monneret1,3 and Fabienne Venet1,3*Abstract
Introduction: Septic syndromes remain the leading cause of mortality in intensive care units (ICU). Septic patients
rapidly develop immune dysfunctions, the intensity and duration of which have been linked with deleterious
outcomes. Decreased mRNA expressions of major histocompatibility complex (MHC) class II-related genes have
been reported after sepsis. We investigated whether their mRNA levels in whole blood could predict mortality in
septic shock patients.
Methods: A total of 93 septic shock patients were included. On the third day after shock, the mRNA expressions
of five MHC class II-related genes (CD74, HLA-DRA, HLA-DMB, HLA-DMA, CIITA) were measured by qRT-PCR and
monocyte human leukocyte antigen-DR (mHLA-DR) by flow cytometry.
Results: A significant correlation was found among MHC class II related gene expressions. Among mRNA markers,
the best prognostic value was obtained for CD74 (HLA-DR antigen-associated invariant chain). For this parameter,
the area under the receiver operating characteristic curve (AUC) was calculated (AUC = 0.67, 95% confidence interval
(CI) = 0.55 to 0.79; P = 0.01) as well as the optimal cut-off value. After stratification based on this threshold, survival
curves showed that a decreased CD74 mRNA level was associated with increased mortality after septic shock
(Log rank test, P = 0.0043, Hazard Ratio = 3.0, 95% CI: 1.4 to 6.5). Importantly, this association remained significant
after multivariate logistic regression analysis including usual clinical confounders (that is, severity scores, P = 0.026,
Odds Ratio = 3.4, 95% CI: 1.2 to 9.8).
Conclusion: Decreased CD74 mRNA expression significantly predicts 28-day mortality after septic shock. After
validation in a larger multicentric study, this biomarker could become a robust predictor of death in septic patients.Introduction
Despite a drop in mortality rate within recent years,
septic syndromes still represent the first cause of death
in intensive care units (ICU) [1].
Septic patients develop immune dysfunctions, the inten-
sity and duration of which have been linked with increased
risk of death or nosocomial infections [2]. The restoration
of normal immune response in patients with immunoad-
juvant therapies now emerges as an innovative therapeutic* Correspondence: fabienne.venet@chu-lyon.fr
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reproduction in any medium, provided the orstrategy in sepsis [2]. Preliminary clinical trials testing
immunostimulating treatments showed promising results
[3]. However, as there is no clinical sign of immune
dysfunctions in ICU patients, a prerequisite is the develop-
ment of robust biomarkers easily accessible to clinicians
so as to identify those patients who could benefit the most
from such therapies.
Among the numerous markers that have been tested
for their capacity to predict mortality in septic patients,
the decreased expression on circulating monocytes of
the major histocompatibility complex (MHC) class II mol-
ecule human leukocyte antigen-DR (HLA-DR) measured
by flow cytometry (mHLA-DR) has proven to be a reliable
predictor of adverse events (death, secondary nosocomial
infections) in critically ill patients when measured 48 hLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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availability of flow cytometers for routine biological ana-
lyses has precluded its use in large multicentric clinical
evaluations and more generally in everyday clinical prac-
tice. Conversely, the ever increasing availability of molecu-
lar biology platforms in routine labs should facilitate the
standardized use of transcriptomic biomarkers. Although
decreased mRNA expressions of MHC class II-related
genes have been reported after sepsis [5,6], association
with mortality has never been specifically investigated.
In the current study, the capacity of MHC class II-
related transcriptomic biomarkers to predict 28-day
mortality after septic shock was evaluated.
Materials and methods
Study design
The study group consisted of 93 septic shock patients
(diagnostic criteria of the American College of Chest
Physician/Society of Critical Care Medicine [7]) admitted
to the surgical or medical ICUs of Lyon-Sud University
hospital and who were alive three days after the onset of
shock. The exclusion criteria were patients under the
age of 18 years old, subjects with aplasia or immunosup-
pressive disease (for example, HIV) and patients that
died before Day 3. Septic shock was defined by an
identifiable site of infection, persisting hypotension
despite fluid resuscitation requiring vasopressor therapy,
and evidence of a systemic inflammatory response
manifested by at least two of the following criteria:
a) temperature >38°C or <36°C; b) heart rate >90 beats/
minute; c) respiratory rate >20 breaths/minute; d) white
blood cell count >12,000/mm3 or <4,000/mm3. Severity
was assessed by the Simplified Acute Physiologic Score
II (SAPS II) calculated at inclusion in the protocol.
Development of organ dysfunction was assessed by the
Sequential Organ Failure Assessment score (SOFA, range:
0 to 24) measured after 24 h of ICU stay. Mortality was
defined as death occurring within 28 days after the onset
of shock. The onset of septic shock was defined as the
beginning of vasopressor therapy. In accordance with
guidelines from the Surviving Sepsis Campaign and from
our ICUs, septic shock patients were rapidly treated with
empiric broad-spectrum antibiotherapy after admission.
Biological analyses were performed on residual blood
after completing routine follow-up performed in the
ICU. PAXgene® and EDTA-anti-coagulated tubes were
collected at the same time from patients at Day 3 or Day
4 after diagnosis of septic shock. This work belongs to a
global study on ICU-induced immune dysfunctions. It
has been approved by our Institutional Review Board for
ethics (“Comité de Protection des Personnes”) which
waived the need for informed consent because this study
was observational and biomarker expressions were
measured on a very low volume of residual blood aftercompletion of routine follow-up. This study is also
registered at the French Ministry of Research and Teach-
ing (#DC-2008-509) and recorded at the Commission
Nationale de l’Informatique et des Libertés.
Flow cytometry
Circulating monocyte HLA-DR expression (mHLA-DR) was
assessed by flow cytometry (NAVIOS; Beckman-Coulter,
Miami, FL) as previously described [8]. Results are expressed
as the number of antibodies bound per cells (AB/C).
RNA extraction, reverse transcription and quantitative PCR
Whole-blood mRNA expressions of five MHC-class II
related genes (HLA-DRA, HLA-DMA, HLA-DMB, CIITA,
CD74) were studied using blood samples collected directly
in PAXgene blood RNA tubes (PreAnalytix, Hilden,
Germany). Total RNA was extracted using the PAXgene
Blood RNA kit (PreAnalytix). Before RNA elution, the
residual genomic DNA was digested using the Rnase-Free
Dnase set (Qiagen, Hilden, Germany). Total RNA was
reverse transcribed into complementary DNA (cDNA)
using SuperScript® VILO TM cDNA Synthetis (Life Tech-
nologies, Grand Island, NY). The gene panel constituting
the MHC II was quantified using q- real time polymerase
chain reaction. Polymerase chain reaction was performed
in a LightCycler instrument using the standard Taqman
Fast Advanced Master Mix PCR kit according to the man-
ufacturer’s instructions (Roche Molecular Biochemicals,
Basel, Switzerland). Thermocycling was performed in a
final volume of 20 μL containing 5 μM of the required
primers, 1 μM of required probe. PCR was performed with
an initial denaturation step of 10 minutes at 95°C, followed
by 45 cycles of a touchdown PCR protocol (10 sec at 95°C,
29 sec annealing at 68°C, and 1 sec extension at 72°C). The
cDNA standards were prepared from purified PCR ampli-
cons obtained with the corresponding primers (Table 1).
The Second Derivative Maximum Method was used
with the LightCycler software to automatically determine
the crossing point for individual samples as previously
described [1]. Standard curves were generated by using
the quadruplicate cDNA standard. Relative standard curves
describing the PCR efficiency of selected genes were
created and used to perform efficiency-corrected quantifi-
cation with the LightCycler Relative Quantification Soft-
ware (Roche Molecular Biochemicals). Gene expression
normalization was performed based on the combination of
two selected housekeeping genes (HPRT1: hypoxanthine
phosphoribosyltransferase 1 and GLYR1: glyoxylate reduc-
tase 1 homolog) and results were expressed as Calibrated
Normalized Relative Quantity (CNRQ) [2]. Both reference
genes (HPRT1 and GLYR1) were selected based on an on-
going project on reference genes usable in genomic studies
in ICU patients. These were selected among a list of other
reference genes based on their stability and the absence of
Table 1 Primer designs
Gene Accession no. Sequence
HLA-DRA NM_019111 5′-GATGCTCCAAGCCCTCTCCCAG-3′ (probe) (22)
5′-GCCTCTTCTCAAGCACTGGGA-3′ (sense) (21)
5′-CCACCAGACCCACAGTCAGG-3′ (antisense) (20)
HLA-DMA NM_006120 5′-TCCCTGAAGCTCCTACTCCAA-3′ (probe) (22)
5′-CTGTGTGGCAAGAAGGTATG-3′ (sense) (20)
5′-TCCTGGCAGTACACTGTGT-3′ (antisense) (19)
HLA-DMB NM_002118 5′-GAGCAGGTGGCTTCGTGGC-3′ (probe) (19)
5′-CATCTTTACAGAGCAGAGCAT-3′ (sense) (21)
5′-ATGTGAAATCCTTTGGAGTCC-3′ (antisense) (21)
CIITA NM_000246 5′-CTCAGAACCCGACACAGACAC-3′ (probe) (21)
5′-CCTGGCTGGAGAAGAAGAG-3′ (sense) (19)
5′-TCCTGGAAGACATACTGGTC-3′ (antisense) (20)
CD74 NM_004355 5′-CCAGCGAGGAGCAGAGTCAC-3′ (probe) (20)
5′-TTATCTCCAACAATGAGCAACT-3′ (sense) (22)
5′-ACAGGAAGTAGGCGGTGGT-3′ (antisense) (19)
HPRT1 NM_000194.2 5′-CAAGTTTGTTGTAGGATATGCCC-3′ (probe) (23)
5′-CCAAAGATGGTCAAGGTCGC-3′ (sense) (20)
5′-GACACAAACATGATTCAAATCC-3′ (antisense) (22)
PPIB NM_000942.4 5′-GGTGAGCATGGCCAACGCAGG-3′ (probe) (22)
5′-GGAGATGGCACAGGAGGAAAGA-3′ (sense) (22)
5′-GGGAGCCGTTGGTGTCTTTG-3′ (antisense) (20)
Design of primers used for the messenger RNA quantification of major histocompatibility class II related genes and selected housekeeping genes using real-time
polymerase chain reaction. CD74, HLA-DR antigen-associated invariant chain; CIITA, class II transactivator; HLA-DR/DM, human leukocyte antigen-DR/DM; HPRT1,
hypoxanthine phosphoribosyltransferase 1; PPIB, peptidylprolyl isomerase B (cyclophilin B).
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tients. This analysis was performed by using the tools avai-
lable via [9] (data not shown).
Statistical analysis
Comparisons between groups were made using the
non-parametric Mann Whitney U-test (survivors vs
non-survivors) for continuous variables and the Pearson
chi-squared test, as appropriate, for categorical data.
Correlation studies were performed with the Spearman’s
rank correlation test. Receiver Operating Curves were per-
formed to determine the cut-off values for CD74 mRNA
or mHLA-DR expressions in regard to prediction of
mortality. The best cut-off value was selected based on
optimized Youden index. Using these thresholds, Kaplan-
Meier survival curves were obtained and differences in
survival between groups were evaluated using Log rank
test. Uni- and multi-variate logistic regression analyses
were used to identify the variables associated with death
and Cox model permitted to estimate the Hazard Ratio
and 95% confidence interval (CI 95%). Backward selection
was used and a P-value of 0.05 was considered as sta-
tistically significant. Because SAPS II and SOFA scores
confirmed the assumed linearity with the outcome(survivors vs non survivors), these variables were included
in the model as continuous variables. Statistical analyses
were performed with SPSS (version 17.0, SPSS, Chicago,
IL, USA) and GraphPad Prism® (version 4.03, GraphPad
Software, La Jolla, CA, USA) softwares.
Results
Ninety-three septic shock patients were included in this
study. Only patients alive and sampled at Day 3 or Day
4 after the onset of shock were included in this cohort
as previous studies showed that the mHLA-DR predict-
ive value on deleterious outcomes (death, nosocomial
infections) after septic shock is maximal at this time point
[4]. Clinical and biological characteristics for this cohort
are listed in Table 2. Twenty-seven patients died within 28
days (mortality = 29%). Median time of death was nine
days after the onset of shock (Q1 to Q3: 5 to 18 days).
The mRNA levels of five MHC class II-related genes
(HLA-DRA, HLA-DMA, HLA-DMB, CIITA and CD74) as
well as mHLA-DR were evaluated in this cohort.
We first observed that whole blood mRNA levels of
these MHC class II genes were highly correlated (Table 3).
Indeed, Spearman’s rank correlation coefficients ranged
from 0.85 to 0.92 illustrating a strong correlation between
Table 2 Demographic and clinical data for septic shock patients
Survivors n = 66 (%) Non-survivors n = 27 (%) P-value Total n = 93 (%)
Male 44 (67) 16 (59) ns 60 (65)
Age* 61 [53 to 73] 65 [55 to 77] ns 62 [54 to 75]
SAPS II on admission* 45 [34 to 54] 57 [46 to 69] <0.0001 48 [35 to 60]
Duration length in ICU* 25 [8 to 37] 12 [5-17] 0.0074 21 [6 to 31]
SOFA* 9 [7-11] 12 [9-12] 0.0013 10 [8-12]
Co-morbidities <0.001
0 44 (65.7) 4 (15.4) 48 (51.61)
1 19 (28.4) 16 (61.5) 35 (37.6)
>2 4 (5.9) 6 (23.1) 10 (10.8)
Type of admission ns
Surgery 30 (46) 10 (37) 40 (43)
Medical 36 (54) 17 (63) 53 (57)
Type of infection ns
Community acquired 32 (49) 18 (67) 50 (54)
Nosocomial 34 (51) 9 (33) 43 (46)
Suspected infection ns
Clinically documented 9 (14) 3 (11) 12 (13)
Microbiologically 55 (83) 22 (85) 78 (84)
Documented
-Bacilli Gram (−) 35 (53) 12 (44) 47 (51)
-Cocci Gram (+) 23 (35) 11 (41) 34 (37)
-Fungi 14 (21) 8 (30) 22 (23)
Primary site of infection 0.0015
-Abdominal 23 (35) 8 (30) 31 (33)
-Pulmonary 27 (41) 15 (55) 42 (43)
-Other 0 (0) 4 (15) 4 (4)
Blood samples were obtained from 93 septic shock patients at Day 3 or Day 4 after the onset of shock. Categorical data are presented as number of cases and
percentages respective to the corresponding patient’s population between brackets. Continuous data (*) are presented as medians and interquartile ranges [Q1 to
Q3]. SAPS II, Simplified Acute Physiologic Score II calculated at inclusion in the protocol; SOFA score, Sequential Organ Failure Assessment score measured after
24 h of ICU stay. Comparisons between groups (survivors vs non-survivors) were made using the non-parametric Mann Whitney U-test for continuous variables
and the Pearson chi-squared test, as appropriate, for categorical data. Most frequent co-morbidities included chronic respiratory failure (n = 10 non-survivors and
4 survivors), chronic cardiac failure (n = 3 non-survivors and 4 survivors), chronic renal failure (n = 3 non-survivors and 5 survivors) and metastatic cancer
(n = 3 non-survivors and 5 survivors). Other co-morbidities included hematologic malignancies, type II diabetes and chronic hepatic failure.
Table 3 Correlations
HLA-DMB HLA-DMA CD74 CIITA HLA-DRA
mHLA-DR 0.52 0.51 0.54 0.49 0.53
HLA-DMB 0.88 0.89 0.85 0.92
HLA-DMA 0.87 0.87 0.92
CD74 0.88 0.87
CIITA 0.87
Major histocompatibility class II-related genes mRNA levels and circulating
monocyte HLA-DR expression (mHLA-DR) were measured in blood samples
obtained from 93 septic shock patients at Day 3 or Day 4 after the onset of
shock. Correlation coefficients are shown (Spearman’s rank correlation test).
CD74, HLA-DR antigen-associated invariant chain; CIITA, class II transactivator;
HLA-DR/DM, human leukocyte antigen-DR/DM.
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but significant correlation was also observed between
these MHC class II gene levels and mHLA-DR measured
by FACS. The highest correlation was found with the
invariant chain, that is, CD74, mRNA expression (r = 0.54;
P <0.0001, Spearman correlation test, Table 3).
These biomarkers’ mRNA expressions were subse-
quently evaluated in survivors vs non-survivors. Non-
survivors presented with significantly lower mHLA-DR
(P = 0.0026, Mann Whitney U-test, Figure 1). In this
cohort, among MHC class II-related genes, only CD74
and HLA-DMA mRNA levels were significantly decreased
in non-survivors (P = 0.0102 and P = 0.0319, respectively,
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Figure 1 MHC class II related genes and protein expressions in survivors and non-survivors after septic shock. Circulating monocyte
HLA-DR expression mHLA-DR – number of antibodies bound per cell (AB/C) was measured by flow cytometry and major histocompatibility class
II related genes mRNA levels were evaluated by qRT-PCR in blood samples obtained from 93 septic shock patients at Day 3 or Day 4 after the
onset of shock. Results are presented as box-plots as well as individual values in survivors (n = 66) and non-survivors (n = 27). Mann Whitney
U-test was used to compare results between groups. CD74, HLA-DR antigen-associated invariant chain, CIITA, class II transactivator; HLA-DR/DM,
human leukocyte antigen-DR/DM.
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curves (AUC) for prediction of 28-day mortality were sub-
sequently calculated for mHLA-DR and CD74. The AUC
was 0.67 for CD74 (95% confidence interval (95% CI): 0.55
to 0.79; P = 0.01) and 0.70 (95% CI: 0.57 to 0.83; P = 0.003)
for mHLA-DR (Figure 2A). Cut-off values were then
determined based on calculation of the optimized Youden
index. Using this cut-off (that is, 0.185), 21 out of 27 non-
survivors could be identified based on a decreased CD74
mRNA expression. To note, among the six non-survivors
that presented a CD74 mRNA level higher than this
calculated threshold, four also had a mHLA-DR value
higher than its respective cut-off value (that is, 1,662).
Kaplan-Meier survival curves were established after
stratification based on calculated thresholds (Figure 2B-C).The survival rates of patients were significantly different
when stratified according to CD74 mRNA expression.
Indeed, patients with higher CD74 mRNA levels had a
significantly better survival compared with patients with
lower expression (P = 0.0043, Log rank test, Hazard
Ratio = 3.0, 95% CI: 1.4 to 6.5, Figure 2B). Similarly,
the survival rate of patients was significantly different
when the cohort was stratified based on mHLA-DR
expression. Patients with mHLA-DR >1,662 presented
with a better survival compared with patients with
decreased mHLA-DR (P <0.0001, Log rank Test, Hazard
ratio = 5.8, 95% CI = 2.6 to 12.9, Figure 2C).
Logistic regression analyses were finally performed to as-
sess if these markers remained independently associated
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Figure 2 Prognostic value of mHLA-DR and CD74 mRNA levels
in septic shock patients. CD74 mRNA level and circulating
monocyte HLA-DR expression (mHLA-DR) were measured in blood
samples obtained from 93 septic shock patients at Day 3 or Day 4
after the onset of shock. A). Receiver operating characteristic curves
were established for these two parameters. The area under the curve
was 0.67 for CD74 (95% confidence interval (95% CI): 0.55 to 0.79;
P = 0.01) and 0.70 (95% CI: 0.57 to 0.83; P = 0.003) for mHLA-DR. B).
Kaplan-Meier survival curves were established after stratification
based on CD74 mRNA level cut-off value (= 0.185, optimized Youden
index). A significant difference was measured between the two
curves (Log rank test, P = 0.0043; Hazard Ratio = 3.0, 95% CI: 1.4
to 6.5). C). Similar analysis was performed for mHLA-DR. Cut-off
value = 1,662 AB/C. Log rank test: P <0.0001, Hazard Ratio = 5.8,
95% CI = 2.6 to 12.9.
Table 4 Multivariate analysis
Univariate Multivariate
P Odds ratio (95% CI) P
mHLA-DR <0.0001 7.8 (2.6 to 23.4) <0.0001
SOFA 0.011 3.3 (1.1 to 10.2) 0.034
SAPS II 0.013 1.7 (0.6 to 5.1) 0.341
CD74 0.006 3.4 (1.2 to 9.8) 0.026
SOFA 0.011 2.3 (0.8 to 6.4) 0.106
SAPS II 0.013 2.1 (0.7 to 5.8) 0.166
Major histocompatibility class II-related gene mRNA levels and circulating
monocyte HLA-DR expression (mHLA-DR) were measured in blood samples
obtained from 93 septic shock patients at Day 3 or Day 4 after the onset of
shock. Uni- and multi-variate logistic regression analyses were used to identify
the variables associated with death (n = 66 survivors and 27 non-survivors) and
Cox model permitted to estimate the Hazard Ratio and 95% confidence
interval (CI 95%). Backward selection was used and a P-value of 0.05 was
considered as statistically significant. Because SAP II and SOFA confirmed the
assumed linearity with the outcome (survivors vs non-survivors), these
variables were included in the model as continuous variables. CD74, HLA-DR
antigen-associated invariant chain; HLA-DR, human leukocyte antigen-DR/DM;
SAPS II, Simplified Acute Physiologic Score II calculated at inclusion in the
protocol; SOFA score, Sequential Organ Failure Assessment score measured
after 24 h of ICU stay.
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lysis, including SOFA and SAPS II scores, decreased CD74
mRNA level (Odds Ratio = 3.4, 95% CI: 1.2 to 9.8, P =
0.026) or diminished mHLA-DR (Odds Ratio = 7.8, 95%CI: 2.6 to 23.4, P <0.001) remained significantly associated
with a higher risk of death after septic shock (Table 4).
Discussion
Despite improvement in patients’ care, septic syndromes
remain a public health challenge [1]. Indeed, a recent
epidemiological study including more than 25,000 patients
in the USA and in Europe showed that overall hospital
mortality from severe sepsis or septic shock is still over
30% [10]. In line with this, one in 1,200 Americans will die
of severe sepsis this year and this is despite numerous
clinical trials testing various therapies and including
thousands of patients [11].
After severe sepsis, the development of a state of
immune suppression is now a well-documented phenome-
non [2,12]. This immunoparalysis is obviously associated
with the occurrence of fatal outcome and in lowering
patients’ resistance to secondary infections. It is now
hypothesized that restoring immune functions in ICU
patients could represent a major therapeutic avenue
[13]. Nevertheless, a crucial aspect is our capacity to
identify only the most immunosuppressed patients
(that is, who could benefit the most from immunosti-
mulating therapies).
In this context, the need for biomarkers of host
response to infection helping the clinicians to 1) identify
the most severe patients (at risk of developing secondary
nosocomial infection); 2) stratify patients before the
initiation of targeted therapy; and 3) to follow response
to treatment are mandatory if we are to decrease mortal-
ity from this major public health challenge [11].
Numerous markers of immune failure have been
described in patients. Among these, the decreased
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sured by flow cytometry has repeatedly been described
as a robust marker of immune dysfunctions in septic
shock patients [4].
The MHC class II molecules, including HLA-DR, are
heterodimers constituted of an α and a β chain (MHC
II-α or HLA-DRA and MHC II-β or HLA-DRB -
Figure 3) and are mainly expressed at the surface of
antigen-presenting cells [14]. MHC class II gene tran-
scription is under the control of class II transactivator A
(CIITA) and factors of the Regulatory Factor X family.
During their synthesis, the α and β chains are complexed
with the invariant chain (that is, CD74 or Ii), therefore
preventing the binding of newly synthesized MHC II α/β
heterodimers with the numerous polypeptides that are
normally present in the endoplasmic reticulum (ER).
CD74 also facilitates the export of class II MHC from
the ER to the Golgi, and then to the late endosomeFigure 3 Major histocompatibility class II related molecules and antig
through the use of IPA (Ingenuity® Systems, www.ingenuity.com).compartment. During this stage, CD74 is broken down
in stages by proteases called cathepsins, leaving only
a small fragment known as CLIP (class II associated
invariant chain peptide), which maintains blockage of the
peptide binding cleft on the MHC molecule. Peptides de-
rived from extracellular proteins that are endocytosed,
ingested in lysosomes are then loaded with the class II
MHC molecule prior to the molecule’s migration to
the cellular membrane. During this process, an MHC
class II-like structure, HLA-DM (heterodimer of HLA-
DMA and HLA-DMB), facilitates CLIP removal and
allows the binding of peptides with higher affinities.
The stable class II MHC is then presented on the cell
surface [14].
In terms of functionality, monocytes with decreased
mHLA-DR have been shown to be unable to mount a
pro-inflammatory response to any bacterial challenge
or to properly present antigens to T cells [4]. In termsen presentation process. The MHC class II network was generated
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shown to be predictive of both fatal outcome and septic
complications after trauma, surgery, pancreatitis, burn
and septic shock [4]. Recently, this parameter has been
used to stratify the administration of GM-CSF in a clin-
ical trial including a small cohort of septic patients [3].
This biomarker-guided GM-CSF therapy appeared safe
and effective in restoring monocyte immunocompetence
and shortening the duration of mechanical ventilation
and hospital/ICU stay. Therefore, the next challenge
would be to design a multicentric clinical trial testing
this biomarker-guided approach in a large cohort of
patients.
However, although an internationally accepted standard-
ized protocol has been designed [15], the measurement of
mHLA-DR by flow cytometry remains not easily access-
ible to clinicians. In particular, strict pre-analytical con-
ditions (delay between sampling and measurement)
have to be respected [16]. Moreover, and most im-
portantly, flow cytometers are not often available 24/7
in hospitals.
Conversely, with the development of rapid molecular
techniques for diagnosis of infection, numerous mRNA
measuring platforms are being developed and becoming
available in hospitals. This would most likely permit the
concomitant development of transcriptomic biomarkers
of host response to infection. We, therefore, asked
whether the measurement of MHC class II-related
genes could predict 28-day mortality after septic shock.
In a cohort of 93 septic shock patients alive three days
after shock, mHLA-DR was measured by flow cytome-
try and CD74, HLA-DRA, HLA-DMA, HLA-DMB and
CIITA mRNA levels were evaluated in whole blood by
qRT-PCR.
We observed that among these five MHC class II-
related genes, the invariant chain (CD74) mRNA was
the best predictor of 28-day mortality after septic shock.
Similarly to our results, several studies investigated the
transcriptional regulation of MHC class II gene expres-
sions in ICU patients. For example, Le Tulzo et al.
described in a small group of septic patients, a decrease
in circulating HLA-DR mRNA levels and a relationship
between HLA-DR mRNA and protein expressions in this
cohort. In particular, a strong correlation between
mHLA-DR and CIITA and HLA-DR mRNA levels was
shown [17]. Similarly, CD74 expression was previously
noted to be markedly decreased in the early phase of
human septic shock either in our group and by other
investigators [5,6] and a parallel recovery of CD74
mRNA and HLA-DR protein expressions was observed
in septic patients [6]. However, none of these studies
was specifically designed to investigate predictive value
of these transcriptomic biomarkers in regard to mortal-
ity after sepsis.In this respect, we observed for the first time that,
among MHC class II genes, a decreased CD74 mRNA
level presented with the best predictive value in regard
to 28-day mortality after septic shock. Importantly,
survival curves showed that patients with low CD74
mRNA level presented with a significantly higher risk of
death than patients with high CD74 expression. Import-
antly, this predictive capacity was maintained after mul-
tivariate analyses, including usual clinical confounders
(SAPS II and SOFA scores). This suggests that, after valid-
ation in a larger multicenter study, the evaluation of CD74
mRNA level could become a robust predictor of mortality
in septic patients.
Moreover, in addition to other studies, these results
highlight the potential of using transcriptomic biomar-
kers in the clinic [18]. The utility of such biomarkers lies
in their capacity to provide timely information beyond
that which is readily available from routine physiologic
data and clinical examination. This additional information
may provide insight into the pathogenesis or prognosis of
a disease process and also aid in a therapeutic decision
[19]. Moreover, they may facilitate titrating therapy or
monitoring the response to intervention [20]. This is all
the more because of the availability in routine labs of mo-
lecular biology platforms that will enable the standardized
and routine monitoring of such biomarkers.
Our study has some limitations. First, beside mHLA-
DR measurement, no specific evaluation of septic patients’
immune functionality was performed in parallel with
CD74 mRNA level. Therefore, we cannot conclude from
the current results that a decreased CD74 mRNA expres-
sion is a marker of immunosuppression in sepsis. This as-
pect needs to be evaluated in a further study. Second, the
evaluation of MHC class II-related gene expressions in
whole blood as opposed to purified cells precludes us
from determining the specific cell type presenting with
these decreased mRNA levels. This could also partly
explain the modest correlation observed between MHC
class II-related genes mRNA levels and mHLA-DR
protein expression measured by flow cytometry. In line,
different cell types in circulating whole blood express
HLA-DR (monocytes, dendritic cells, B lymphocytes and
activated T lymphocytes) which may have different inten-
sities and kinetics of MHC class II expression regulation.
While most studies have focused on monocytes, very few
data are available regarding the regulation of HLA-DR
expression on these other cell types after septic shock. In
addition, as protein vs mRNA markers were measured,
this low correlation could be explained by post-transla-
tional regulation mechanisms or differences in kinetics
of expression (mRNA being expressed before the protein).
In addition, our study was not designed to specifically in-
vestigate the mechanisms leading to decreased mHLA-DR
expression after septic shock (translational or post-
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were included in the study. Therefore, biomarkers of
fulminant septic shock were not evaluated here. Since
severity scores were measured at admission, the de-
sign of this study may have been in favor of a better
prognostic value of our markers vs these scores. Fi-
nally, this study was not designed to directly compare
the performances of CD74 mRNA level vs mHLA-DR
in predicting 28-day mortality after septic shock but
to identify the most promising prognostic marker
among several MHC class II related genes. Obviously,
a dedicated study is now mandatory to confirm these
preliminary results.
Conclusions
In total, these results show that decreased invariant
chain/CD74 mRNA expression significantly predict
28-day mortality in septic shock patients alive at Day
3. After validation in a large multicenter study, this
biomarker could become a robust predictor of death
in septic patients.
Key messages
 Decreased HLA-DR antigen-associated
invariant chain (CD74) mRNA expression
significantly predicts 28-day mortality three days
after septic shock.
 Upon validation in a large multicentric study,
this biomarker could become a robust predictor
of death in septic patients and a relevant tool to
monitor patients’ immune status.
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